000			03411nam a2200397 i 4500
988			_aSpringer_BiomedLife_2019
999			_c115787 _d115787 _x1
001			115787
003			ESmaUEC
005			20230110040237.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190702s2019 si | s |||| 0|eng d
020			_a9789811380198
024	7		_a10.1007/978-981-13-8019-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQC552 .H5 _b2019 EB
100			_aGanai, Shabir Ahmad _eauthor. _4aut _4http://id.loc.gov/vocabulary/relators/aut _9672013
245	1	0	_aHistone Deacetylase Inhibitors - Epidrugs for Neurological Disorders _cby Shabir Ahmad Ganai.
250			_a1st ed. 2019.
264		1	_aSingapore _bSpringer International Publishing _c2019
300			_a1 recurso en línea (XVII, 93 páginas) _b 8 ilustraciones, 5 ilustraciones a color
336			_aTexto _btxt _2rdacontent
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aChapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.
520	3		_aThis book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors' therapeutic efficacy against various neurological complications.
650		7	_9671765 _aTubos electrónicos _2embne
776	0	8	_iPrinted edition: _z9789811380181
776	0	8	_iPrinted edition: _z9789811380204
776	0	8	_iPrinted edition: _z9789811380211
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-13-8019-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b12/2019 _eIG _zSI